MDACC Study No:2007-0044 ( NCT No: NCT00614653)
Title:Phase I Trial of radiotherapy with concurrent bevacizumab, erlotinib and capecitabine for locally advanced pancreatic cancer
Principal Investigator:Sunil Krishnan
Treatment Agent:Bevacizumab; Capecitabine; Erlotinib; Radiotherapy
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in
combination with radiation to patients with pancreatic cancer.
Hide details for General InformationGeneral Information

Disease Group:Pancreas
Phase of Study:Phase I
Treatment Agents:Bevacizumab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:n/a
Supported By:Genentech, Inc.
Return Visit:Follow-up 4-6 weeks after chemoradiation treatment. During maintenance therapy
monthly (+/- 1 week)
Home Care:n/a

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sunil Krishnan
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-2361
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults